GSK/Adolor Entereg “Approvable” Pending CV Risk Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s second “approvable” letter for the postoperative ileus treatment requests development of a risk management plan and 12-month safety data from an ongoing trial.